Dr. Melinda L. Yushak
Claim this profileEmory University Hospital/Winship Cancer Institute
Studies Skin Cancer
Studies Melanoma
11 reported clinical trials
24 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRAF positive
2Melanoma
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Melinda L. Yushak is currently running
Tuvusertib + Avelumab
for Merkel Cell Skin Cancer
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Recruiting1 award Phase 210 criteria
Tazemetostat + Dabrafenib + Trametinib
for Melanoma
This phase I/II trial investigates the best dose, possible benefits and/or side effects of tazemetostat in combination with dabrafenib and trametinib in treating patients with melanoma that has a specific mutation in the BRAF gene (BRAFV600) and that has spread to other places in the body (metastatic). Tazemetostat, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tazemetostat in combination with dabrafenib and trametinib may stabilize BRAFV600 mutated melanoma.
Recruiting1 award Phase 1 & 224 criteria
More about Melinda L. Yushak
Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Melinda L. Yushak has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- RP1
Breakdown of trials Melinda L. Yushak has run
Skin Cancer
Melanoma
Cutaneous Melanoma
Merkel Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melinda L. Yushak specialize in?
Melinda L. Yushak focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Melinda L. Yushak currently recruiting for clinical trials?
Yes, Melinda L. Yushak is currently recruiting for 4 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Melinda L. Yushak has studied deeply?
Yes, Melinda L. Yushak has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Melinda L. Yushak?
Apply for one of the trials that Melinda L. Yushak is conducting.
What is the office address of Melinda L. Yushak?
The office of Melinda L. Yushak is located at: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory University Hospital/Winship Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.